Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD44 | P16070 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 3/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.36 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | CASP1 | P29466 | 1/20 | 0.33 |
| ▸ | CASP7 | P55210 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | FDPS | P14324 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30645118 | 1.00 | CD44 (0.39) | CD44TSHRALOX15TDP1TAAR1 | |
| Sulfuric Acid SCHEMBL14830445 | 0.90 | TTR (0.38) | CD44TSHRALOX15TDP1TAAR1 | |
| SCHEMBL3482721 | 0.85 | CD44 (0.46) | CD44TSHRALOX15TDP1TAAR1 | |
| SCHEMBL9687589 | 0.85 | KDM4E (0.40) | CD44TSHRALOX15TAAR1CYP3A4 | |
| SCHEMBL10624720 | 0.82 | TAAR1 (0.45) | TSHRALOX15TDP1TAAR1ALDH1A1 | |
| SCHEMBL720119 | 0.81 | CYP3A4 (0.43) | CD44TSHRALOX15TDP1CYP3A4 | |
| SCHEMBL249418 | 0.81 | TDP1 (0.44) | TSHRALOX15TDP1TAAR1CYP3A4 | |
| SCHEMBL14895143 | 0.80 | MMP2 (0.41) | TSHRALOX15TDP1TAAR1CYP3A4 | |
| SCHEMBL1224647 | 0.80 | TDP1 (0.34) | TSHRALOX15TDP1TAAR1CYP3A4 | |
| SCHEMBL4640275 | 0.79 | TAAR1 (0.52) | CD44TAAR1SMN1; SMN2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5061289-A | AS DEVELOPERS | WELLA AKTIENGESELLSCHAFT (DE) | 1991-10-29 | — | — | US | claimed |
| US-4762875-A | Water based printing inks for plastic and metal surfaces | GOLD MARVIN H (US) | 1988-08-09 | — | — | US | claimed |
| US-4762865-A | Epoxy coatings for computer hard disks and metal coil decoration and protection | GOLD MARVIN H (US) | 1988-08-09 | — | — | US | claimed |
| US-4652388-A | WATER BASED DISPERSION; ADHESIVE PLASTICIZER AND POLYMER | GOLD MARVIN H (US) | 1987-03-24 | — | — | US | claimed |
| CN-111344281-B | Potassium channel inhibitors substituted benzimidazoles | 阿塞西翁制药公司 | 2023-11-14 | — | — | CN | disclosed |
| US-11274092-B2 | Potassium channel inhibitors | ACESION PHARMA APS (DK) | 2022-03-15 | — | — | US | disclosed |
| US-20210188804-A1 | NOVEL POTASSIUM CHANNEL INHIBITORS | ACESION PHARMA APS (DK) | 2021-06-24 | — | — | US | disclosed |
| CN-109153667-B | Novel potassium channel inhibitors | 阿塞西翁制药公司 | 2021-04-02 | — | — | CN | disclosed |
| US-20200216398-A1 | NOVEL POTASSIUM CHANNEL INHIBITORS | ACESION PHARMA APS (DK) | 2020-07-09 | — | — | US | disclosed |
| CN-111344281-A | Potassium channel inhibitors of substituted benzimidazoles | 阿塞西翁制药公司 | 2020-06-26 | — | — | CN | disclosed |
| EP-3668841-A1 | SUBSTITUTED BENZIMIDAZOLES AS POTASSIUM CHANNEL INHIBITORS | Acesion Pharma ApS (DK) | 2020-06-24 | — | — | EP | disclosed |
| EP-3419973-B1 | NOVEL POTASSIUM CHANNEL INHIBITORS | ACESION PHARMA APS (DK) | 2020-04-08 | — | — | EP | disclosed |
| US-20060111322-A1 | Indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation | AGOURON PHARMACEUTICALS, INC. | 2006-05-25 | — | — | US | disclosed |
| US-20050239855-A1 | Indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation | AGOURON PHARMACEUTICALS, INC. | 2005-10-27 | — | — | US | disclosed |
| US-6919461-B2 | Indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation | AGOURON PHARMACEUTICALS, INC. (US) | 2005-07-19 | — | — | US | disclosed |
| US-20030139463-A1 | Indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation | REICH SIEGFRIED HEINZ (US) | 2003-07-24 | — | — | US | disclosed |
| US-6555539-B2 | For treating cancer and other disease states associated with unwanted angiogenesis and/or cellular proliferation such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, psoriasis | AGOURON PHARMACEUTICALS | 2003-04-29 | — | — | US | disclosed |
| US-20020161022-A1 | Indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation | AGOURON PHARMACEUTICALS | 2002-10-31 | — | — | US | disclosed |
| EP-1250326-A2 | INDAZOLE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND THEIR USE FOR MEDIATING OR INHIBITING CELL PROLIFERATION | AGOURON PHARMACEUTICALS, INC. (US) | 2002-10-23 | — | — | EP | disclosed |
| WO-2001053268-A2 | INDAZOLE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND THEIR USE FOR MEDIATING OR INHIBITING CELL PROLIFERATION | AGOURON PHARMACEUTICALS, INC. (US) | 2001-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200216398-A1 | NOVEL POTASSIUM CHANNEL INHIBITORS | KCNN1, KCNN2, KCNJ2 | CD44 4677/4885TSHR 3421/4885ALOX15 3621/4885 |
| US-20210188804-A1 | NOVEL POTASSIUM CHANNEL INHIBITORS | KCNJ2, KCNN2, KCNN1 | CD44 4651/4885TSHR 3607/4885ALOX15 3501/4885 |
| US-11274092-B2 | Potassium channel inhibitors | KCNJ2, KCNJ11, KCNJ1 | CD44 4499/4885TSHR 3019/4885ALOX15 3158/4885 |
| US-20050239855-A1 | Indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation | CDK3, MKI67, ROCK1 | CD44 1346/4885TSHR 2787/4885ALOX15 1358/4885 |
| US-20020161022-A1 | Indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation | CDK3, MKI67, ROCK1 | CD44 1346/4885TSHR 2787/4885ALOX15 1358/4885 |
| US-20030139463-A1 | Indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation | CDK3, MKI67, ROCK1 | CD44 1346/4885TSHR 2787/4885ALOX15 1358/4885 |
| US-20060111322-A1 | Indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation | MKI67, CCNI, CDK3 | CD44 633/4885TSHR 3448/4885ALOX15 647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.